ArticleClinical pharmacokinetics2025

Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.

Ronilda D'Cunha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.